The identification of tumor “oncogenic drivers” and the subsequent development of targetedtherapy represented a milestone in the treatment of lung cancer over the last years. Tumor genotyping hasbeen incorporated into therapeutic decision making of advanced non-small cell lung cancer (NSCLC) sincehas become clear that individuals with actionable molecular alterations receiving a matched targeted agentcertainly live longer and better. The recent understanding of biological mechanisms underlying cancerimmune evasion has allowed the development of a new class of immunomodulatory agents which are ableto reactivate host immune-response, offering the potential for long-term disease control and survival in asignificant subgroup of lung cancer patients. The complementary therapeutic effects of these two differentapproaches suggested intriguing potential for therapeutic synergy with combination strategies. Indeed,immunotherapy could consolidate the dramatic but transient tumor responses achieved with targeted therapyinto long-term survival benefit, due to the induction of specific anti-tumor memory. However, the greatemphasis and expectations linked to immune-targeted combinations have been mostly disappointed by theinitial controversial results of early-phase trials, raising relevant concerns about the use of these combinationsfor lung cancer treatment. This review briefly summarizes the basis of immunogenicity and immune escapein oncogene addicted NSCLC, providing an updated overview of clinical trials, with the final aim of definingthe current unmet needs of immuno-targeted combinations in clinical practice.
|Numero di pagine||9|
|Rivista||Translational Cancer Research|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes